Paul Perreault, CSL Behring CEO

CSL's $11.7B buy­out hits an­titrust de­lay — is it a sign of what's to come?

CSL’s mam­moth Vi­for Phar­ma buy­out will have to wait a few more months, the com­pa­ny re­vealed on Wednes­day, as ex­perts won­der whether an­titrust reg­u­la­tors will slow things down across the en­tire in­dus­try.

While CSL pre­vi­ous­ly ex­pect­ed to close its $11.7 bil­lion Vi­for ac­qui­si­tion this June, the com­pa­ny said on Wednes­day that the reg­u­la­to­ry ap­proval process is tak­ing a bit longer than ex­pect­ed. Some an­titrust au­thor­i­ties have ap­proved the trans­ac­tion, but oth­ers re­main out­stand­ing, Vi­for said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.